Nanomedicine (London, England)最新文献_第8页

Non-viral gene delivery systems in the treatment of oral cancers: a promising future. 非病毒基因传递系统在口腔癌治疗中的应用前景广阔。

Nanomedicine (London, England) Pub Date : 2025-05-14 DOI: 10.1080/17435889.2025.2503693

Seiichi Yamano, Kenji Inoue

引用次数: 0

The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems. 新兴的替代品PEG脂质纳米颗粒RNA递送系统的好处。

Nanomedicine (London, England) Pub Date : 2025-05-10 DOI: 10.1080/17435889.2025.2500917

Manon Berger, Manon Degey, Alicia Curnel, Brigitte Evrard, Géraldine Piel

引用次数: 0

How can nanotechnology be leveraged to produce multifunctional contrast agents to improve imaging and diagnostics? 如何利用纳米技术生产多功能造影剂来改善成像和诊断？

Nanomedicine (London, England) Pub Date : 2025-05-08 DOI: 10.1080/17435889.2025.2501515

Junxi Yi, Yun-Sheng Chen

引用次数: 0

How could the affordable, reliable and continuous production of lipid nanoparticles revolutionize healthcare? 脂质纳米颗粒的可负担、可靠和连续生产是如何彻底改变医疗保健的？

Nanomedicine (London, England) Pub Date : 2025-05-06 DOI: 10.1080/17435889.2025.2500911

Luke Burroughs, Diane J Burgess

引用次数: 0

Harnessing extracellular vesicles to deliver genetic medicine for cardiac repair. 利用细胞外囊泡为心脏修复提供基因药物。

Nanomedicine (London, England) Pub Date : 2025-05-06 DOI: 10.1080/17435889.2025.2500913

Songpu Xie, Nazma F Ilahibaks, Zhiyong Lei, Joost P G Sluijter

引用次数: 0

Can nanoparticulate formulations of vancomycin and vancomycin derivatives improve antibiotic therapy? 万古霉素和万古霉素衍生物的纳米粒制剂能改善抗生素治疗吗？

Nanomedicine (London, England) Pub Date : 2025-05-05 DOI: 10.1080/17435889.2025.2500905

Eric Mühlberg, Gert Fricker, Philipp Uhl

引用次数: 0

The distinct properties of high-density lipoprotein nanoparticles as ocular drug delivery vehicles. 高密度脂蛋白纳米颗粒作为眼部给药载体的独特特性。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-02-21 DOI: 10.1080/17435889.2025.2469489

Tatsuya Murakami, Haruka Kurita

引用次数: 0

(Re)evolution in nanoparticles-loaded microneedle delivery systems: are we getting closer to a clinical translation? （再）纳米粒子负载微针输送系统的进化：我们离临床转化更近了吗？

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/17435889.2025.2492538

Antonio José Guillot, Ana Melero

{"title":"(Re)evolution in nanoparticles-loaded microneedle delivery systems: are we getting closer to a clinical translation?","authors":"Antonio José Guillot, Ana Melero","doi":"10.1080/17435889.2025.2492538","DOIUrl":"10.1080/17435889.2025.2492538","url":null,"abstract":"The deposition of drug-loaded nanoparticles within the skin structure has been a challenge due to the inexorable skin barrier function. Unless specific nanoparticles like liposomes and lipid-based related vesicles, most nanoparticles cannot penetrate the epidermal layers by themselves. This is the reason why microneedle-based systems are nowadays the most straightforward systems in skin research. They can greatly bypass the stratum corneum and deposit the supramolecular cargo entities in the dermal layers, which can perform specific features such as drug-controlled release, specific targeting or stimuli-responsive behaviors. At this point, after more than 20 years of research using this nanoparticle-microneedle combination and all the positive results, the clinical experience is still so limited. Therefore, how is it possible that the everlasting promise of the clinical translation of these systems has not reached a real clinical practice? In this piece of work, based on authors' review, a series of limiting factors as the regulatory framework and guidelines are identified and discussed, while it is highlighted that revolutionary advances in the biomedical field such as 3D-printing technology and microfluidics will contribute to accelerate the clinical translation of nanoparticle-microneedle-based devices and make possible their use and entrance to the biomedical market.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1195-1207"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening. 新兴的基于纳米颗粒的乳腺癌筛查x射线成像造影剂。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-22 DOI: 10.1080/17435889.2025.2496129

Katherine J Mossburg, Diego Barragan, Nathaniel H O, Andrea C Kian, Andrew D A Maidment, David P Cormode

{"title":"Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.","authors":"Katherine J Mossburg, Diego Barragan, Nathaniel H O, Andrea C Kian, Andrew D A Maidment, David P Cormode","doi":"10.1080/17435889.2025.2496129","DOIUrl":"10.1080/17435889.2025.2496129","url":null,"abstract":"Breast cancer is one of the most common types of cancer, however, preventive screening has contributed to a significant reduction in mortality over the past four decades. The first-line screening methods for breast cancer, such as mammography and tomosynthesis, are x-ray-based modalities. Unfortunately, their cancer detection rates are low in patients with dense breasts. These, and other high-risk women, are now encouraged to receive supplemental screening. The supplemental imaging methods are diverse, including ultrasound, MRI, nuclear imaging, and X-ray-based modalities such as breast CT and contrast-enhanced mammography/tomosynthesis. Due to their low cost and wide availability, x-ray-based modalities see significant clinical use worldwide. These techniques benefit from the use of contrast agents, which are currently iodinated small molecules designed for other purposes. Consequently, developing new contrast agents that are specifically for breast cancer screening is of interest. This review describes these modalities and the nanoparticle-based contrast agents being researched for their enhanced performance. The relevant parameters for nanoparticle-based contrast agent design are evaluated, including contrast generation and potential biointeractions. Iodinated agents are discussed for comparison. Nanoparticles covered include silver sulfide, silver telluride, gold, and bismuth sulfide-based agents, among others. Finally, perspectives on future developments in this field are offered.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1149-1166"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. 撤回声明：四碘甲乙酸偶联PLGA纳米颗粒：一种治疗耐药乳腺癌的纳米医学方法。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1080/17435889.2025.2488633

引用次数: 0